THREAD Research, a company focused on supporting decentralized clinical trials, will work with Amazon Web Services to decrease trial costs while improving research access and data quality.
The two companies will develop advanced machine learning architecture and artificial intelligence models to automate processes, according to a Tuesday release. The cloud-enabled platform will reduce inefficiencies and auto-populate data workflows that are currently performed manually.
Decentralized clinical trials have taken off in the past year as the pandemic forced pharmaceutical companies to pivot to digital tactics to continue vital research. CROs have been adding new capabilities and products to meet the need, with THREAD becoming the latest company to announce a new offering in the space.
“With AWS, we are exponentially scaling our DCT platform to provide real-time access to data and insights that are essential to personalize and optimize research that meets the needs of the study and our customers,” John Reites, THREAD's CEO, said in a news release.
The automation will reduce the startup time to onboard customers by up to 30%, and the technology will allow up to 25% cost-savings for customers when pre-completing data.
“By combining the security, scale and agility of AWS’s cloud and machine learning technology with THREAD's advanced DCT platform, we are empowering our customers to automate data capture and storage and at the same time providing predictive forecasts to better run studies and decrease the time it takes to conduct research,” Scott Pearson, THREAD's chief product officer, said in the news release. “This is the future of modern clinical research.”
The move follows THREAD's recent acquisition of tech provider inVibe and purchase of research consultant service company Modus Outcomes.